Compare ALEMBIC PHARMA with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA FDC LTD. ALEMBIC PHARMA/
FDC LTD.
 
P/E (TTM) x 15.6 17.5 89.0% View Chart
P/BV x 3.6 2.4 151.4% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 ALEMBIC PHARMA   FDC LTD.
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
FDC LTD.
Mar-18
ALEMBIC PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs664319 208.2%   
Low Rs412164 251.5%   
Sales per share (Unadj.) Rs208.761.6 338.6%  
Earnings per share (Unadj.) Rs31.09.9 311.6%  
Cash flow per share (Unadj.) Rs37.112.0 310.2%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.273.2 197.1%  
Shares outstanding (eoy) m188.52174.40 108.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.63.9 65.8%   
Avg P/E ratio x17.424.3 71.5%  
P/CF ratio (eoy) x14.520.2 71.8%  
Price / Book Value ratio x3.73.3 113.1%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,46142,118 240.9%   
No. of employees `000NA5.5 0.0%   
Total wages/salary Rs m7,4672,167 344.6%   
Avg. sales/employee Rs ThNM1,943.7-  
Avg. wages/employee Rs ThNM391.7-  
Avg. net profit/employee Rs ThNM313.7-  
INCOME DATA
Net Sales Rs m39,34710,751 366.0%  
Other income Rs m94510 18.4%   
Total revenues Rs m39,44111,260 350.3%   
Gross profit Rs m8,7362,267 385.4%  
Depreciation Rs m1,152351 327.9%   
Interest Rs m18414 1,315.0%   
Profit before tax Rs m7,4932,411 310.8%   
Minority Interest Rs m11-5 -225.0%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568671 233.5%   
Profit after tax Rs m5,8441,735 336.8%  
Gross profit margin %22.221.1 105.3%  
Effective tax rate %20.927.8 75.1%   
Net profit margin %14.916.1 92.0%  
BALANCE SHEET DATA
Current assets Rs m19,5777,213 271.4%   
Current liabilities Rs m14,8962,104 708.1%   
Net working cap to sales %11.947.5 25.0%  
Current ratio x1.33.4 38.3%  
Inventory Days Days9054 164.7%  
Debtors Days Days4528 163.6%  
Net fixed assets Rs m27,0976,865 394.7%   
Share capital Rs m377175 215.2%   
"Free" reserves Rs m26,81112,586 213.0%   
Net worth Rs m27,18812,761 213.1%   
Long term debt Rs m4,9936 83,216.7%   
Total assets Rs m47,77815,041 317.6%  
Interest coverage x41.7173.2 24.1%   
Debt to equity ratio x0.20 39,058.7%  
Sales to assets ratio x0.80.7 115.2%   
Return on assets %12.611.6 108.5%  
Return on equity %21.513.6 158.1%  
Return on capital %23.619.0 124.5%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4531,889 1,029.9%   
Fx outflow Rs m6,0650-   
Net fx Rs m13,3881,889 708.8%   
CASH FLOW
From Operations Rs m8,1201,498 541.9%  
From Investments Rs m-7,556201 -3,757.3%  
From Financial Activity Rs m590-1,694 -34.8%  
Net Cashflow Rs m1,15310 11,197.1%  

Share Holding

Indian Promoters % 74.1 68.9 107.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 4.7 61.7%  
FIIs % 9.1 7.5 121.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 19.0 73.2%  
Shareholders   49,328 23,730 207.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS